Exact Sciences
EXAS
#1152
Rank
S$24.86 B
Marketcap
S$131.04
Share price
-0.12%
Change (1 day)
52.05%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

P/E ratio for Exact Sciences (EXAS)

P/E ratio as of December 2025 (TTM): -19.0

According to Exact Sciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -19.0094. At the end of 2024 the company had a P/E ratio of -10.1.

P/E ratio history for Exact Sciences from 2002 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-10.1
2022-14.0-37.82%
2021-22.5-4.41%
2020-23.5-81.93%
2019-130197.25%
2018-43.8-16.6%
2017-52.5548.88%
2016-8.1049.13%
2015-5.43-75.46%
2014-22.129.95%
2013-17.041.51%
2012-12.0

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Myriad Genetics
MYGN
-1.69-91.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Antares Pharma
ATRS
16.4-186.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Veracyte
VCYT
122-739.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Biocept
BIOC
-0.0085-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
13.2-169.42%๐Ÿ‡ซ๐Ÿ‡ท France

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.